The genetics of complex cholestatic disorders. by Hirschfield, G, Chapman, R, Karlsen, T, Lammert, F, Lazaridis, K, Mason, A

Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. by Boberg, K, Chapman, R, Hirschfield, G, Lohse, A, Manns, M, Schrumpf, E

A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis by Dennis, A, Mouchti, S, Kelly, M, Fallowfield, JA, Hirschfield, G, Pavlides, M, Banerjee, R

Spleen extracellular volume fraction and platelet count/spleen volume ratio are accurate non-invasive markers of portal hypertension by Levick, C, Pavlides, M, Breen, D, Nash, K, Hirschfield, G, Tripathi, D, Robson, M, Neubauer, S, Barnes, E

Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis by Dennis, A, Kelly, MD, Fernandes, C, Mouchti, S, Fallowfield, JA, Hirschfield, G, Pavlides, M, Harrison, S, Chakravarthy, MV, Banerjee, R, Sanyal, A

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis by Jeffery, H, Braitch, M, Bagnall, C, Hodson, J, Jeffery, L, Wawman, R, Wong, L, Birtwistle, J, Bartlett, H, Lohse, A, Hirschfield, G, Dyson, J, Jones, D, Hubscher, S, Klenerman, P, Adams, D, Oo, Y

THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC by Kowdley, K, Luketic, V, Jones, D, Chapman, R, Burroughs, A, Hirschfield, G, Poupon, R, Schramm, C, Vincent, C, Rust, C, Pares, A, Mason, A, Castelloe, E, Sciacca, C, Boehm, O, Pruzanski, M, Shapiro, D

AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC by Kowdley, K, Jones, D, Luketic, V, Chapman, R, Burroughs, A, Hirschfield, G, Poupon, R, Schramm, C, Vincent, C, Rust, C, Pares, A, Mason, A, Sciacca, C, Beecher-Jones, T, Bohm, O, Castelloe, E, Pruzanski, M, Shapiro, D, Grp, O

Targeting C-reactive protein for the treatment of cardiovascular disease. by Pepys, M, Hirschfield, G, Tennent, G, Gallimore, JR, Kahan, M, Bellotti, V, Hawkins, P, Myers, R, Smith, M, Polara, A, Cobb, A, Ley, S, Aquilina, J, Robinson, C, Sharif, I, Gray, G, Sabin, C, Jenvey, M, Kolstoe, SE, Thompson, D, Wood, S

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis by Kowdley, K, Luketic, V, Chapman, R, Hirschfield, G, Poupon, R, Schramm, C, Vincent, C, Rust, C, Parés, A, Mason, A, Marschall, H, Shapiro, D, Adorini, L, Sciacca, C, Beecher-Jones, T, Böhm, O, Pencek, R, Jones, D, Obeticholic Acid Pbc Monotherapy Study Group

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. by Liu, J, Hov, JR, Folseraas, T, Ellinghaus, E, Rushbrook, S, Doncheva, N, Andreassen, O, Weersma, R, Weismüller, T, Eksteen, B, Invernizzi, P, Hirschfield, G, Gotthardt, D, Pares, A, Ellinghaus, D, Shah, T, Juran, B, Milkiewicz, P, Rust, C, Schramm, C, Müller, T, Srivastava, B, Dalekos, G, Nöthen, M, Herms, S

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis by Fickert, P, Hirschfield, G, Denk, G, Marschall, H, Altorjay, I, Färkkilä, M, Schramm, C, Spengler, U, Chapman, R, Bergquist, A, Schrumpf, E, Nevens, F, Trivedi, P, Reiter, F, Tornai, I, Halilbasic, E, Greinwald, R, Pröls, M, Manns, M, Trauner, M, European Psc Norudca Study Group

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease by Williamson, K, Lytvyak, E, De Krijger, M, Trivedi, P, Estes, D, Yu, L, Pratt, D, De Vries, A, Daretti, L, Liu, C, Bowlus, C, Marschall, H, Montano-Loza, A, Chapman, R, Van Der Woude, C, Marzioni, M, Keshav, S, Ponsioen, C, Hirschfield, G, Levy, C

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. by de Vries, E, de Krijger, M, Färkkilä, M, Arola, J, Schirmacher, P, Gotthardt, D, Goeppert, B, Trivedi, P, Hirschfield, G, Ytting, H, Vainer, B, Buuren, H, Biermann, K, Harms, M, Chazouilleres, O, Wendum, D, Kemgang, A, Chapman, R, Wang, L, Williamson, K, Gouw, A, Paradis, V, Sempoux, C, Beuers, U, Hübscher, S, Verheij, J, Ponsioen, C

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases by Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C